Browse treatments

…ould be further explored regarding a genetic factor.Conclusions Initial therapy was associated with improved survival and reduced PAH progressi…

…ss and chest wall restriction. Finally, the association between anti-reflux therapy and ILD identifies a potential modifiable risk factor that meri…

…Angiotensin-Converting Enzyme inhibitor (ACEi) intervention and glucocorticoid avoidance in high-risk SSc patients, the rate of end-stage kidney disease…

…t heart catheterization, gastrointestinal dysmotility requiring enteral/parenteral nutrition, digital ulcer (DU) or gangrene, or death.Results 275 patients …

…oximately 15% of patients progressing to severe forms requiring nutritional support [10.1093/rheumatology/key350]. Loss of physiological motility i…

… address clinical manifestations or modify disease progression. CD19-targeted chimeric antigen receptor (CAR)-T cell therapy shows promise, with the potential to induce deep and sustained …

…fication of 112 IU/mL and 30 IU/mL, respectively.Results During LTV prophylaxis, 5 pts (11.9%) exhibited CMV DNA >112 IU/mL (median[IQR]: 296[1…

…ground Syphilis and other STIs are resurging among PLWH. In the ART era, syphilis may transiently perturb immune markers and trigge…

…liness, fidelity, treatment retention, and service capacity for CAB/RPV LA delivery. Organizational redesign incorporating centralized …

…We consecutively enrolled virally suppressed PWH (≥18 years, on ART, HIV RNA <50 copies/mL) receiving two HZ/su vaccine doses 2–6 m…

…clerosis (SSc). Unlike the skin, GI disease does not respond to immunosuppression and generally worsens with time. We have previously analysed ga…

…ogic profile was confirmed one year later. The patient received immunosuppressive therapy with D-penicillamine for seven years, after which she was lost …